Novavax Inc. said Monday its virus-like particle vaccines were effective in preclinical studies in protecting against different strains of the bird flu virus, and its shares surged in after-hours trading.
The studies involved two of Novavax's H5N1 influenza virus-like particle, or VLP vaccines, one targeting the Indonesia strain of pandemic flu and another targeting the Viet Nam strain. Mice and ferrets inoculated with each vaccine were protected when challenged with both strains of the virus.
The studies were conducted in collaboration with the University of Pittsburgh, and the data was submitted for peer-review publication. The U.S. Centers for Disease Control and Prevention also will conduct live challenge studies using Novavax's VLP pandemic influenza vaccines, according to a company release.
"We expect the CDC to further confirm these new data before we enter the clinic this year," Rick Bright, Novavax's vice president of global influenza programs, said in a release.
Shares of Novavax added 33 cents, or 8.1 percent, to $4.42 in aftermarket activity, after gaining 2 cents to end at $4.09 on the Nasdaq Stock Market where they have traded between $2.84 and $8.39 in the past year.
Source: Bio-Bio Technology